TMBIM6 antagonist-1 (BIA, 0.5-10 μM, 3 days) significantly and dose-dependently inhibits cell viability in HT1080, MCF7, MDA-MB-2341 and SKBR3 cells, with IC50 values of 1.7?±?0.1?μM for HT1080, 2.6?±?0.4?μM for MCF cells, 2.6?±?0.5?μM for MDA-MB-231 cells, and 2.4?±?0.4?μM for SKBR3 cells, respectively.TMBIM6 antagonist-1 (BIA, 10 μM) treatment decreases cell migration in HT1080, MCF7, MDA-MB-231, and SKBR3 cells, not TMBIM6 KO HT1080 cells. has not independently confirmed the accuracy of these methods. They are for reference only.
TMBIM6 antagonist-1 (1?mg/kg, IP 5 days per week during 25 days) significantly impaires cell-driven tumor growth. has not independently confirmed the accuracy of these methods. They are for reference only.